These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28088786)

  • 21. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.
    Pereira ASA; Amaral MS; Vasconcelos EJR; Pires DS; Asif H; daSilva LF; Morales-Vicente DA; Carneiro VC; Angeli CB; Palmisano G; Fantappie MR; Pierce RJ; Setubal JC; Verjovski-Almeida S
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006873. PubMed ID: 30365505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
    Zhang JJ; Chen JT; Hua L; Yao KH; Wang CY
    Biomed Pharmacother; 2017 Jan; 85():472-478. PubMed ID: 27890434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
    Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer.
    He Z; Xu H; Meng Y; Kuang Y
    Biomed Pharmacother; 2017 Apr; 88():902-910. PubMed ID: 28178620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
    Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
    Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
    Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
    Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
    Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).
    Liu BL; Sun KX; Zong ZH; Chen S; Zhao Y
    Oncotarget; 2016 Feb; 7(6):6649-64. PubMed ID: 26673619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker.
    Chen S; Sun KX; Liu BL; Zong ZH; Zhao Y
    Oncotarget; 2016 May; 7(19):27538-51. PubMed ID: 27050373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2.
    Yu W; Zhang G; Lu B; Li J; Wu Z; Ma H; Wang H; Lian R
    Gene; 2016 Feb; 577(2):193-201. PubMed ID: 26656176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
    Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
    Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
    Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
    Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression.
    Bing L; Hong C; Li-Xin S; Wei G
    Arch Gynecol Obstet; 2014 Sep; 290(3):533-41. PubMed ID: 24699721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma.
    Lu J; Ji H; Tang H; Xu Z
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1610-1617. PubMed ID: 30131250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
    Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
    Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.